"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Ultra-TechneKow Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Ultra-TechneKow DTE (Technetium Tc 99m Generator) is a source of sodium pertechnetate Tc 99m for use in the preparation of FDA-approved diagnostic radiopharmaceuticals. Common side effects include allergic reactions.
Ultra-TechneKow DTE is administered by intravenous injection and the dosage depends on the imaging procedure being performed. Ultra-TechneKow DTE may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Ultra-TechneKow DTE should be used only if prescribed. This drug passes into breast milk. Formula feedings should be substituted for breastfeedings.
Our Ultra-TechneKow DTE (Technetium Tc 99m Generator) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Ultra-TechneKow FDA Prescribing Information: Side Effects
Allergic reactions including anaphylaxis have been reported infrequently following the administration of Sodium Pertechnetate Tc 99m.
Read the entire FDA prescribing information for Ultra-TechneKow (Technetium Tc 99m Generator For the Production of Sodium Pertechnetate Tc 99m Injection)
Additional Ultra-TechneKow Information
Report Problems to the Food and Drug Administration
Find out what women really need.